Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31019967 | 0.89 | ERN1 (0.40) | PTGS2PTGS1 | |
| SCHEMBL25199320 | 0.89 | ERN1 (0.40) | PTGS2PTGS1 | |
| SCHEMBL31019964 | 0.83 | POLB (0.35) | — | |
| SCHEMBL25187642 | 0.83 | POLB (0.35) | — | |
| SCHEMBL31019954 | 0.83 | EPAS1 (0.36) | PTGS2PTGS1PSEN1PSEN2APH1B | |
| SCHEMBL31019948 | 0.82 | PTGS2 (0.36) | PTGS2PTGS1PSEN1PSEN2APH1B | |
| SCHEMBL20530220 | 0.81 | MEN1 (0.38) | — | |
| SCHEMBL30428083 | 0.80 | TRPA1 (0.36) | PTGS2PTGS1TRPA1 | |
| SCHEMBL25193465 | 0.79 | MAPK1 (0.38) | PTGS2PTGS1PSEN1PSEN2APH1B | |
| SCHEMBL30426876 | 0.79 | MAPK1 (0.38) | PTGS2PTGS1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051275-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | HANA PHARM CO., LTD. (KR) | 2025-02-13 | — | — | US | disclosed |
| EP-4434966-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | Hana Pharm. Co. Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118451060-A | Pyrrole derivative or pharmaceutically acceptable salt thereof and composition for preventing, improving or treating gastrointestinal diseases comprising the same as active ingredient | 合娜制药株式会社 | 2024-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051275-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | STOM, SI, PGC | PTGS2 970/4885PTGS1 672/4885PSEN1 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.